NTRA
Natera, Inc.
Latest Form 4:Sale$2.1MbyFesko John (PRESIDENT, CHIEF BUS. OFFICER) · filed Aug 29, 2026
Natera, Inc. (NTRA) has 153 SEC Form 4 filings (500 transaction rows) in the rolling window, disclosed by 12 distinct insiders. Most recent filing: Aug 29, 2026.
The most active filer is Director Sheena Jonathan with 32 filings. Insiders have net sold $142.7M over the trailing 6 months.
- Industry:Medical - Diagnostics & Research
- CEO:Steven Leonard Chapman
- Employees:6,140
- HQ:Austin, TX, US
- IPO:2015-07-01
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$306.1M
reported sales (SEC code S)
Unique Insiders
12
in the rolling window
Market Cap
$46.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 6,517 | $2.1M | Aug 29 | SEC ↗ | |
| CO-FOUNDER | Sale | 6,000 | $2.0M | Aug 15 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 2,000 | $642K | Aug 8 | SEC ↗ | |
| CO-FOUNDER | Sale | 9,150 | $2.9M | Aug 8 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 317 | $85K | Aug 6 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 478 | $131K | Aug 6 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 3,076 | $819K | Aug 6 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 295 | $79K | Aug 6 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,410 | $906K | Aug 6 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 334 | $90K | Aug 6 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 731 | $196K | Aug 6 | SEC ↗ | |
| CO-FOUNDER | Sale | 109 | $29K | Aug 6 | SEC ↗ | |
| CO-FOUNDER | Sale | 288 | $75K | Jul 30 | SEC ↗ | |
| CO-FOUNDER | Sale | 191 | $49K | Jul 30 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 1,718 | $448K | Jul 30 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 884 | $230K | Jul 30 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 1,003 | $255K | Jul 30 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,010 | $263K | Jul 30 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,204 | $306K | Jul 30 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 782 | $204K | Jul 30 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 931 | $237K | Jul 30 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 2,190 | $570K | Jul 30 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 3,580 | $910K | Jul 30 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 782 | $204K | Jul 30 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 2,419 | $614K | Jul 30 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,863 | $465K | Jul 30 | SEC ↗ | |
| CO-FOUNDER | Sale | 1,500 | $411K | Jul 18 | SEC ↗ | |
| Director | Sale | 135 | $37K | Jul 18 | SEC ↗ | |
| CO-FOUNDER | Sale | 3,150 | $837K | Jul 16 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 1,000 | $280K | Jul 9 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 16,800 | $4.6M | Jul 7 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,000 | $819K | Jul 7 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 33,600 | $8.5M | Jun 27 | SEC ↗ | |
ROSENMAN HERMFirst in 6 months | Director | Sale | 16,530 | $4.1M | Jun 27 | SEC ↗ |
| CO-FOUNDER | Sale | 1,500 | $330K | Jun 23 | SEC ↗ | |
Chapman Rowan EFirst in 3 months | Director | Sale | 2,964 | $643K | Jun 18 | SEC ↗ |
| CO-FOUNDER | Sale | 3,150 | $665K | Jun 18 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 50,000 | $10.7M | Jun 17 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 50,000 | $10.7M | Jun 17 | SEC ↗ | |
Marcus Gail BoxerFirst in 7 months | Director | Sale | 11,000 | $2.4M | Jun 10 | SEC ↗ |
| CEO AND PRESIDENT | Sale | 41,124 | $9.1M | Jun 6 | SEC ↗ | |
BOTHA ROELOFFirst in 4 months | Director | Sale | 78,000 | $17.2M | Jun 3 | SEC ↗ |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,000 | $655K | Jun 3 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,652 | $335K | May 29 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 1,438 | $292K | May 29 | SEC ↗ | |
| CO-FOUNDER | Sale | 3,150 | $657K | May 16 | SEC ↗ | |
| CO-FOUNDER | Sale | 1,500 | $302K | May 16 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 722 | $149K | May 7 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 6,986 | $1.5M | May 7 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 313 | $65K | May 6 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 482 | $101K | May 6 | SEC ↗ | |
| Insider | Sale | 107 | $22K | May 6 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,405 | $694K | May 6 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 291 | $60K | May 6 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 902 | $186K | May 6 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 330 | $68K | May 6 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,993 | $407K | Apr 30 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 3,070 | $595K | Apr 30 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 5,838 | $1.2M | Apr 30 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 1,688 | $345K | Apr 30 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 2,182 | $445K | Apr 30 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 1,861 | $380K | Apr 30 | SEC ↗ | |
| Insider | Sale | 473 | $96K | Apr 30 | SEC ↗ | |
| Insider | Sale | 3,071 | $603K | Apr 30 | SEC ↗ | |
| CO-FOUNDER | Sale | 1,500 | $299K | Apr 21 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 8,400 | $1.7M | Apr 3 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,000 | $607K | Apr 3 | SEC ↗ | |
| Insider | Sale | 3,070 | $608K | Mar 20 | SEC ↗ | |
| Insider | Sale | 1,500 | $300K | Mar 20 | SEC ↗ | |
Chapman Rowan EFirst in 3 months | Director | Sale | 122 | $23K | Mar 17 | SEC ↗ |
Rabinowitz MatthewFirst in 4 months | EXECUTIVE CHAIRMAN | Sale | 75,000 | $14.3M | Mar 16 | SEC ↗ |
Rabinowitz MatthewFirst in 4 months | EXECUTIVE CHAIRMAN | Sale | 75,000 | $14.2M | Mar 16 | SEC ↗ |
Rabinowitz MatthewFirst in 4 months | EXECUTIVE CHAIRMAN | Sale | 50,000 | $9.8M | Mar 16 | SEC ↗ |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 915 | $187K | Mar 11 | SEC ↗ | |
| CO-FOUNDER | Sale | 127 | $26K | Mar 11 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 785 | $160K | Mar 11 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 707 | $144K | Mar 11 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 5,623 | $1.1M | Mar 11 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 1,745 | $356K | Mar 11 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 8,398 | $1.6M | Mar 10 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,000 | $600K | Mar 3 | SEC ↗ | |
| CO-FOUNDER | Sale | 3,070 | $615K | Mar 3 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 3,950 | $790K | Mar 3 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,000 | $694K | Feb 4 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,639 | $378K | Feb 4 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 85,299 | $19.7M | Feb 4 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 4,725 | $1.1M | Feb 4 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 6,939 | $1.6M | Feb 4 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 3,594 | $830K | Feb 4 | SEC ↗ | |
| CO-FOUNDER | Sale | 435 | $100K | Feb 4 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 1,334 | $308K | Feb 4 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 784 | $189K | Jan 29 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 2,413 | $573K | Jan 29 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,867 | $430K | Jan 29 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 886 | $213K | Jan 29 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 1,000 | $238K | Jan 29 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 784 | $189K | Jan 29 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 928 | $221K | Jan 29 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 2,322 | $559K | Jan 29 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 3,648 | $867K | Jan 29 | SEC ↗ | |
| CO-FOUNDER | Sale | 291 | $70K | Jan 29 | SEC ↗ | |
| CO-FOUNDER | Sale | 191 | $45K | Jan 29 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,013 | $244K | Jan 29 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,200 | $285K | Jan 29 | SEC ↗ | |
| Insider | Sale | 1,500 | $366K | Jan 27 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 23,948 | $5.6M | Jan 22 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 37,175 | $9.0M | Jan 22 | SEC ↗ | |
| CO-FOUNDER | Sale | 2,981 | $700K | Jan 22 | SEC ↗ | |
| CO-FOUNDER | Sale | 3,163 | $742K | Jan 22 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 19,234 | $4.5M | Jan 22 | SEC ↗ | |
| SEC. AND CHIEF LEGAL OFFICER | Sale | 438 | $103K | Jan 22 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 71,932 | $16.9M | Jan 22 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 1,590 | $374K | Jan 22 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 23,205 | $5.4M | Jan 22 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 293 | $69K | Jan 22 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 17,806 | $4.2M | Jan 22 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 339 | $80K | Jan 22 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 3,848 | $881K | Jan 6 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 2,951 | $676K | Jan 6 | SEC ↗ | |
| CO-FOUNDER | Sale | 1,500 | $339K | Dec 22 | SEC ↗ | |
| CO-FOUNDER | Sale | 3,070 | $697K | Dec 17 | SEC ↗ | |
ROSENMAN HERMFirst filing | Director | Sale | 48,419 | $11.0M | Dec 16 | SEC ↗ |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 4,692 | $1.1M | Dec 16 | SEC ↗ | |
Chapman Rowan EFirst in 3 months | Director | Sale | 4,366 | $1.1M | Dec 9 | SEC ↗ |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,000 | $714K | Dec 3 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 4,400 | $1.0M | Dec 3 | SEC ↗ | |
BOTHA ROELOFFirst filing | Director | Sale | 75,000 | $17.7M | Nov 26 | SEC ↗ |
Baynes Roy D.First filing | Insider | Sale | 5,112 | $1.1M | Nov 21 | SEC ↗ |
Baynes Roy D.First filing | Insider | Sale | 7,668 | $1.7M | Nov 21 | SEC ↗ |
| CO-FOUNDER | Sale | 10,000 | $2.3M | Nov 21 | SEC ↗ | |
| CO-FOUNDER | Sale | 4,000 | $920K | Nov 21 | SEC ↗ | |
| CO-FOUNDER | Sale | 3,070 | $591K | Nov 12 | SEC ↗ | |
| CO-FOUNDER | Sale | 1,500 | $312K | Nov 12 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 3,000 | $596K | Nov 4 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 22,900 | $4.6M | Nov 4 | SEC ↗ | |
| CO-FOUNDER | Sale | 4,000 | $800K | Nov 4 | SEC ↗ | |
Marcus Gail BoxerFirst filing | Director | Sale | 122 | $24K | Nov 4 | SEC ↗ |
| CEO AND PRESIDENT | Sale | 160,703 | $32.1M | Nov 3 | SEC ↗ | |
| EXECUTIVE CHAIRMAN | Sale | 17,100 | $3.4M | Nov 3 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 781 | $150K | Oct 29 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 2,415 | $462K | Oct 29 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,867 | $356K | Oct 29 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 2,335 | $449K | Oct 29 | SEC ↗ | |
| CEO AND PRESIDENT | Sale | 3,680 | $705K | Oct 29 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 781 | $150K | Oct 29 | SEC ↗ | |
| PRESIDENT, CHIEF BUS. OFFICER | Sale | 928 | $178K | Oct 29 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,008 | $194K | Oct 29 | SEC ↗ | |
| PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,198 | $229K | Oct 29 | SEC ↗ |
Related companies
Natera, Inc. is in the Healthcare sector.